To determine whether the addition of plerixafor improves the proportion of patients with lymphoma who collect ≥ 8 x 106 CD34+ cells/kg within two days by 25% compared to the historical estimate of 42% with etoposide and G-CSF.
To determine whether patients achieving collection of ≥ 8 x 106 CD34+ cells/kg have a 15% one year survival advantage relative to the historical estimate of 68% among patients mobilizing ≥ 2 but < 8 x 106 CD34+ cells/kg with etoposide and G-CSF.
To demonstrate that patients receiving ≥ 8 x 106 CD34+ cells/kg have more rapid neutrophil and platelet recovery and earlier hospital discharge than those receiving < 8 x 106 CD 34+ cells/kg.
To compare overall survival and progression-free survival between patients receiving ≥8 x 106 CD34+ cells/kg and those receiving <8 x 106 CD34+ cells/kg.
To compare number of days of apheresis required to achieve goal, transfusion requirements, hospitalization costs, need for remobilization between groups.
To evaluate whether peripheral CD34+ cell count correlates with graft content of CD34+ cells.
Participants must be 18 years of age or older but not more than 78 years old
Have biopsy-confirmed non-Hodgkin lymphoma, of any type
Must be eligible for autologous transplantation according to institutional guidelines
Eastern Cooperative Oncology Group performance status of 0 or 1
Karnofsky performance status of 70 to 100
Negative for HIV
Prior to the start of mobilization, must have:
Absolute neutrophil count of ≥ 1.2 x 109/L
Platelet count of ≥ 100 x 109/L
Creatinine clearance ≥ 30 mL/minute
All patients must be able to comprehend and sign informed consent.
If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose. Female patients will undergo pregnancy test prior to stem cell mobilization therapy.